CCL2 and breast carcinoma: Cells of the myeloid lineage, particularly macrophages, comprise the largest immune subpopulations within the ER+ TME, like other breast cancer subtypes [44,45,55,68,69], and many clinical ER+ tumors express high levels of macrophage chemoattractants, such as CCL2 and CCL5 [70].